Ethics, public policy and behavioral genetics

Israel Medical Association Journal

Volumn 5, Issue 2, 2003, Pages 83-86

  Glick, David ^a   Soreq, Hermona ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Diagnosis; In vitro fertilization; Late onset; Pharmacogenomics; Polygenic

Indexed keywords

DIAGNOSIS; GENES; GENETIC ENGINEERING; PUBLIC POLICY;

POLYMORPHISM;

BEHAVIORAL RESEARCH;

NEUROLEPTIC AGENT;

BEHAVIOR; BEHAVIOR DISORDER; BEHAVIOR GENETICS; CONFIDENTIALITY; DISEASE COURSE; DNA MICROARRAY; EMPLOYABILITY; ENVIRONMENTAL FACTOR; FERTILIZATION IN VITRO; GENE IDENTIFICATION; GENETIC DISORDER; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC PROCEDURES; GENETIC RISK; GENETIC SCREENING; GENETIC TRAIT; GENOME; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; HUMAN RIGHTS; MEDICAL ETHICS; MEDICAL GENETICS; OCCUPATION; PRENATAL DIAGNOSIS; REVIEW; SOCIAL BEHAVIOR;

GENETICS AND REPRODUCTION;

CONFIDENTIALITY; FERTILIZATION IN VITRO; GENETICS, BEHAVIORAL; HUMAN GENOME PROJECT; HUMANS; PRENATAL DIAGNOSIS; PUBLIC POLICY;

EID: 0037303567     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Garrod AE. Inborn errors of metabolism (Croonian Lecturers). Lancet 1908;ii: 1-7, 73-9, 142-8, 214-20.
2. Lewohl JM., Dodd PR, Mayfield RD, Harris RA. Application of DNA microarrays to study human alcoholism. J Biomed Sci 2001;8:28-36.
3. Rannala B. Finding genes influencing susceptibility to complex diseases in the post-genome era. Am J Pharmacogenomics 2001; 1: 203-21.
4. Shifman S, Bronstein M, Sternfeld M, et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 2002;71:1296-302.
5. McLellan F. Controversy over deliberate conception of a deaf child. Lancet 2002;359:1315.
6. Zammatteo N, Hamels S, De Longueville F, et al. New chips for molecular biology and diagnostics. Biotechnol Annu Rev 2002;8:85-101.
7. Polyak K, Riggins GJ. Gene discovery using the serial analysis of gene expression technique: Implications for cancer research. J Clin Oncol 2001;19:2948-58.
8. Krishnan KR. Biological risk factors in late life depression. Biol Psychiatry 2002;52:185-92.
9. Evans WR, Relling MV. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999;286:487-91.
10. Tribut O, Lessard Y, Reymann JM, Allain H, Bentue-Ferrer D. Pharmacogenomics. Med Sci Monit 2002;8:RA152-63.
11. Collins FM. Current treatment approaches to type 2 diabetes mellitus: Successes and shortcomings. Am J Manag Care 2002;8:S460-71.
12. Prasad S, Semwal P, Deshpande S, Bhatia T, Nimgaonkar VL, Thelma BK. Molecular genetics of schizophrenia: Past, present and future. J Biosci 2002;27:35-52.
13. Bird TD. Risks and benefits of DNA testing for neurogenetic disorders. Semin Neurol 1999;19:253-9.
14. Bird TD, Bennett RL. Why do DNA testing? Practical and ethical implications of new neurogenetic tests. Ann Neurol 1995;38:141-6.
15. Anonymous. Sweden plans to pay sterilization victims. The New York Times 27 January 1999:A8.
16. Badminton MN, Elder GH. Management of acute and cutaneous porphyrias. Int J Clin Pract 2002;56:272-8.
17. Savulescu J. Procreative beneficence: Why we should select the best children. Bioethics 2001;15:413-26.
18. Spriggs M. Genetically selected baby free of inherited predisposition to early-onset Alzheimer's disease. J Med Ethics 2002;28:290.